GoodRx (NASDAQ:GDRX), the leading U.S. prescription savings platform, announced on April 9, 2026, a strategic collaboration with Eli Lilly and Company to improve affordability for the newly launched oral GLP-1 medication, Foundayo™ (orforglipron).
The partnership aims to provide transparent, low-cost options for the millions of Americans seeking obesity care outside of traditional insurance coverage.
Through this initiative, eligible self-pay patients can access Foundayo for a starting price of $149 per month.
This pricing represents the lowest available discounted cash price at launch and is available at more than 70,000 pharmacies nationwide.
The move is seen as a significant win for patients who have previously been priced out of the high-demand GLP-1 market, where list prices for branded treatments often exceed $1,000 per month.
In addition to the Foundayo launch, GoodRx is expanding its offerings for Eli Lilly’s injectable portfolio.
Eligible patients can now access Zepbound® (tirzepatide) KwikPen® starting at $299 per month.
By offering both oral and injectable options, the partnership addresses varying patient preferences and clinical needs within the weight management space.
Foundayo, which received FDA approval on April 1, 2026, is the first once-daily oral non-peptide GLP-1.
Its oral delivery and significantly lower price point through GoodRx are expected to ease the supply chain pressures currently affecting the injectable weight loss market.